Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 18/20 | 0.80 |
| ▸ | INSR | P06213 | 9/20 | 0.80 |
| ▸ | LYN | P07948 | 7/20 | 0.80 |
| ▸ | LCK | P06239 | 7/20 | 0.80 |
| ▸ | KDR | P35968 | 7/20 | 0.80 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.80 |
| ▸ | FLT3 | P36888 | 6/20 | 0.80 |
| ▸ | FLT4 | P35916 | 5/20 | 0.80 |
| ▸ | KIT | P10721 | 5/20 | 0.80 |
| ▸ | FLT1 | P17948 | 5/20 | 0.80 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.80 |
| ▸ | CSF1R | P07333 | 5/20 | 0.80 |
| ▸ | BLK | P51451 | 5/20 | 0.80 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.80 |
| ▸ | MARK3 | P27448 | 4/20 | 0.80 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.80 |
| ▸ | NEK2 | P51955 | 4/20 | 0.80 |
| ▸ | LIMK1 | P53667 | 4/20 | 0.80 |
| ▸ | STK3 | Q13188 | 4/20 | 0.80 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1986239 | 1.00 | IGF1R (0.80) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL1984596 | 1.00 | IGF1R (0.80) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL1989235 | 0.90 | IGF1R (0.66) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL1989237 | 0.90 | IGF1R (0.66) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL3683012 | 0.90 | IGF1R (0.66) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL1989788 | 0.89 | IGF1R (1.00) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL1984354 | 0.89 | IGF1R (0.97) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL1985084 | 0.89 | IGF1R (1.00) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL1983460 | 0.89 | IGF1R (0.97) | IGF1RINSRLYNLCKKDR | |
| SCHEMBL1985083 | 0.89 | IGF1R (1.00) | IGF1RINSRLYNLCKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390369-B1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2005-11-09 | — | — | EP | claimed |
| US-20040180911-A1 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | claimed |
| EP-1390369-A1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2004-02-25 | — | — | EP | claimed |
| WO-2002092599-A1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO (2,3-D) PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | claimed |
| EP-1737493-B1 | INHIBITORS OF INSULIN-LIKE GROWTH FACTOR RECEPTOR -1 FOR INHIBITING TUMOR CELL GROWTH | DANA FARBER CANCER INST INC (US) | 2011-06-29 | — | — | EP | disclosed |
| US-7781393-B2 | Methods for inhibiting tumor cell growth | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20080193462-A1 | Inhibiting tumor cell growth in subject by administering to said subject a combination of a cytotoxic or a chemotherapeutic agent and a composition comprising an insulin-like growth factor receptor-1 (IGF-1R) inhibitor; demonstrating specific approaches to enhance therapeutic window of IGF-1R inhibition | NATIONAL INSTITUTES OF HEALTH- DIRECTOR DEITR | 2008-08-14 | — | — | US | disclosed |
| US-7326699-B2 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | NOVARTIS AG (CH) | 2008-02-05 | — | — | US | disclosed |
| EP-1476192-B1 | METHODS AND COMPOSITIONS FOR TREATING HYPERPROLIFERATIVE CONDITIONS | DANA FARBER CANCER INST INC (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1390369-B1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| US-20050215564-A1 | Methods and compositions for treating hyperproliferative conditions | DANA-FARBER CANCER INSTITUTE INC. | 2005-09-29 | — | — | US | disclosed |
| EP-1476192-A1 | METHODS AND COMPOSITIONS FOR TREATING HYPERPROLIFERATIVE CONDITIONS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040180911-A1 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | disclosed |
| EP-1390369-A1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2004-02-25 | — | — | EP | disclosed |
| WO-2003068265-A1 | METHODS AND COMPOSITIONS FOR TREATING HYPERPROLIFERATIVE CONDITIONS | DANA-FARBER CANCER INSTITUTE INC. (US) | 2003-08-21 | — | — | WO | disclosed |
| WO-2002092599-A1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO (2,3-D) PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193462-A1 | Inhibiting tumor cell growth in subject by administering to said subject a combination of a cytotoxic or a chemotherapeutic agent and a composition comprising an insulin-like growth factor receptor-1 (IGF-1R) inhibitor; demonstrating specific approaches to enhance therapeutic window of IGF-1R inhibition | IGF1R, IGFBP1, IGFBP2 | IGF1R 1/4885INSR 14/4885LYN 1634/4885 |
| US-20040180911-A1 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | TYMP, DPYD, TYMS | IGF1R 3898/4885INSR 2996/4885LYN 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.